GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Capex-to-Operating-Income

Serina Therapeutics (Serina Therapeutics) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Serina Therapeutics's Capital Expenditure for the six months ended in Mar. 2024 was $-0.01 Mil. Its Operating Income for the six months ended in Mar. 2024 was $-2.32 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Serina Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Serina Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Capex-to-Operating-Income Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
Capex-to-Operating-Income
- -

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
Capex-to-Operating-Income - - - - -

Competitive Comparison of Serina Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Serina Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Capex-to-Operating-Income falls into.



Serina Therapeutics Capex-to-Operating-Income Calculation

Serina Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.01) / -2.27
=N/A

Serina Therapeutics's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.014) / -2.321
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Serina Therapeutics  (AMEX:SER) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Serina Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Serina Therapeutics (Serina Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines